Introduction
Renal cell carcinoma (RCC) is frequently associated with inactivating mutations or methylation of the von Hippel Lindau (VHL) gene [1] . Mutated VHL resulted in unbridled hypoxiainducible factor (HIF)-driven transcription of various proangiogenic factors [2] , including vascular endothelial growth factor (VEGF) [3] . Numerous inhibitors of the VEGF receptor or ligand are active against advanced ccRCC. Unfortunately, resistance to these agents is universal via mechanisms that to date have been poorly elucidated. Thus, newer agents with unique mechanisms of action are warranted in ccRCC drug development.
Several studies show that upregulation of the PI3K/AKT pathway is associated with poorer prognosis in patients with RCC [4] [5] [6] [7] [8] [9] . RCC patients treated with anti-VEGF therapy who have upregulation of components of the PI3K pathway have shorter progression-free survival (PFS) [4, 5] . In a randomized trial of sorafenib versus sorafenib plus interferon alpha (IFN) in metastatic RCC, we found that AKT S473 phosphorylation was the single strongest predictor of clinical outcome in a panel of clinical and tissue variables [4] . Similarly, analysis of nephrectomy samples in patients who received presurgical bevacizumab showed that upregulation of AKT was associated with a shorter PFS and poorer overall survival [5] . Multiple papers provide a strong rationale for targeting the PI3 kinase pathway in RCC [10] [11] [12] .
We, therefore, hypothesized that blockade of AKT in patients who are refractory to VEGF-targeted therapy would be superior to blocking the downstream TORC1 complex, thus eliminating one of the key drivers of tumor growth and resulting in prolongation of PFS. To clinically test this hypothesis, we evaluated MK-2206, a selective allosteric inhibitor of AKT [13] , in a clinical trial. MK-2206 does not bind to the active site of AKT, and consequently does not compete with either ATP or peptide substrate for binding to AKT. It is equally potent against the two human AKT isoforms, AKT1 and AKT2, and 5-fold less potent against AKT3. The antiproliferative potency of MK-2206 was evaluated against a panel of tumor cell lines using in vitro proliferation and viability assays. To date, no formal efficacy studies have been performed with MK-2206 in RCC. Based on these clinical and preclinical data, we designed a randomized phase 2 clinical trial comparing MK-2206 to everolimus in refractory RCC. We also performed genomic analyses of available tissue in patients who received MK-2206.
Patients and methods

Inclusion criteria
This multicenter, randomized phase 2 clinical trial was approved and sponsored by the National Cancer Institute and by the respective institutional review boards of the participating sites. In order to be included in this study, adult patients (18 years old) with ECOG performance status 0 or 1 must have provide consent, and had histologically confirmed metastatic or unresectable RCC. Patients had measurable disease by RECIST and acceptable end-organ function. Patients were required to have documented disease progression following nephrectomy and treatment with anti-VEGF agents and no prior treatment with an mTOR inhibitor or any other investigational agent.
Study design
Patients were enrolled on the study and randomized 2:1 to receive MK-2206 or everolimus, respectively. Patients received MK-2206 at the starting dose of 200 mg orally once weekly or everolimus at a staring dose of 10 mg PO once daily, based on phase I study data demonstrating significant AKT pathway blockade [14] . Courses were repeated every 4 weeks in the absence of disease progression or unacceptable toxicity according to the NCI Common Terminology Criteria for Adverse Events (version 4.0). Dose modifications were performed according to interim toxicities.
Outcome measures
The primary goal of the study was to estimate the PFS of patients who received either MK-2206 or everolimus. Patients were evaluated for response every eight weeks using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [15] . PFS was defined as the duration of time from randomization to time of progression or death, whichever occurred first. A co-primary objective of the study was to assess the safety of MK-2206, which was evaluated by review of systems, physical examination, laboratory evaluation and adverse events, graded by NCI-CTCAE 4.0. Secondary efficacy outcomes included evaluation of overall response rate (ORR), overall survival (OS) and time to treatment failure (TTF). An exploratory objective of the study was to assess the impact of genomic alterations on outcome in patients treated with MK-2206 or everolimus.
Statistical analysis
The anticipated median PFS was 4.9 months and 8.2 months for the everolimus and MK2206 arms, respectively. One interim futility analysis was planned when a total of 38 events occurred. The O'Brien-Fleming stopping boundaries using Lan-DeMets spending function were used for early rejection of futility boundaries. Assuming that the alternative hypothesis held, 105 patients with 75 events provided 81% power to reject the null hypothesis. A separate stopping rule was created for toxicity, based on continuous monitoring rules. All statistical tests were twosided and P value less than 0.05 was considered statistically significant.
Results
Patient characteristics
Demographic and baseline characteristics of the 43 patients (14 in the everolimus arm and 29 in the MK-2206 arm) are summarized in Table 1 . The median age was 63.5 years in the everolimus group and 59 years in the MK-2206 group. The majority of the patients in both groups were male and Caucasian. More than 65% of the patients had performance status 1 and around 60% were in the Memorial Sloan Kettering Cancer Center (MSKCC) intermediate risk group. In both groups, the majority of the patients had clear cell histology (85.7% and 72.4%) and lung metastasis (57.1% and 82.7%). The majority of the patients were previously treated with sunitinib in both groups: 50% in the everolimus group and 58.6% in MK-2206 group.
Efficacy
The trial met futility criteria at the planned interim analysis, and a total of 43 patients was enrolled. One of the patients was randomized to the MK-2206 group but received everolimus and left the study before restaging. In addition, one patient in the everolimus group left the study before restaging. Overall, 13 patients in the everolimus group and 28 patients in the MK-2206 group were evaluable for efficacy ( Table 2) .
The primary efficacy endpoint was PFS. Table 2 summarizes the number of patients, number of events (i.e., progression or death) and the median OS along with the 95% confidence interval (CI) by treatment arm. PFS was calculated using the KaplanMeier method by treatment arm ( Figure 1A ). The median PFS for the MK-2206 and the everolimus group was 3.68 months (95% CI, 1.77-5.75) and 5.98 months (95% CI, 5.03-not estimable), respectively. The secondary efficacy endpoint was OS ( Figure 1B) . The median OS for MK-the 2206 and the everolimus group was 23.5 months (95% CI, 10.7-37.4) and 15.7 months (95% CI, 6.5-not estimable), respectively.
In the MK-2206 group, one patient experienced a confirmed objective complete response (CR) and three patients had partial response (PR). Representative imaging studies of the patient with complete response are demonstrated in supplementary Figure S1 , available at Annals of Oncology online. Eleven patients in each group experienced a best response of stable disease (SD). Two patients in everolimus group and 13 patients in the MK-2206 group experienced progressive disease as the best response. Degree of response is shown with waterfall plots in supplemen tary Figure S2 , available at Annals of Oncology online.
Toxicity
The most common adverse events in the MK-2206 group were maculo-papular rash (79.3%), hyperglycemia (69%) and fatigue (62.1%) ( Table 3 ). In the everolimus group, the most common adverse events were fatigue (78.6%), hyperlipidemia (64.3%) and hyperglycemia (64.3%). In the MK-2206 group, 24.1% and 27.6% of the patients developed grade 3 or 4 hyperglycemia and maculo-papular rash, respectively. There were very few grade 3 or 4 adverse events in the everolimus group. Table 4 summarizes rate of dose reduction and the reasons patients came off therapy.
Genomic analyses
Targeted DNA sequencing of tumor samples was analyzed to identify molecular correlates of response to treatment in the MK-2206 and everolimus treatment groups. Results were classified into three groups (D: deleterious mutation, N: neutral mutation, U: unknown mutation) according to mutation types using the Condel database. The unknown mutations were further classified according to the characteristics of the mutation (sv: splice variant, fs: frameshift variant, ns: nonsynonymous variant, *: premature stop codon, cl: in-frame codon loss). The mean copy number ratio of the length of each gene in every sample was calculated and filtered by only the high deletion (H.DEL) and high amplification (H.AMP) copy number calls (supplementary Figure S3 , available at Annals of Oncology online). Analyses were performed with Fisher's exact test to determine whether individual genes or pathways were significantly mutated in the PD versus the non-PD group. Four pathways were significantly altered in the PD group versus the non-PD group, as described in Table 5 . According to the analysis, the TP53-ATM genes drove the pathway results. 57.1% of the patients in the PD group had either deleterious TP53 mutations (V143M, G266V, R273C) or ATM mutations (S978F, fs_2077) or deletion. In contrast, none of the patients in the non-PD group had TP53 or ATM defects.
In the MK-2206-treated group, four patients (13.8%) had sarcomatoid histological features. Three of those patients were in the PD group and one of them was in the non-PD group. Two of those patients in the PD group had either TP53 or ATM defects. To search for candidate predictive biomarkers, particular attention was paid to patients who developed a PR or CR. These patients did not have activating mutations in the PI3K pathway, or any shared genomic features.
Discussion
Our study reveals that targeting AKT induces a very different pattern of response than when TORC1 is targeted with everolimus. Whereas patients treated with everolimus for the large part had minimal changes in tumor size, MK-2206 induced a fairly dichotomous response dynamic, with three patients demonstrating profound response, and a number of patients exhibiting rapid growth kinetics (supplementary Figure S2 , available at Annals of Oncology online). Of equal note is the overall survival between agents, with a numerical advantage for the MK2206 treated group, although this difference did not reach statistical significance. Another difference between MK-2206 and everolimus was the side effect profile (Table 3) . A significant number of patients on MK-2206 developed a rash, whereas this side effect was less frequent and less troublesome for patients who received everolimus.
Similar efficacy and toxicity findings were observed in recently reported trials testing PI3K inhibitors. BEZ235, a dual inhibitor of PI3K, and mTOR showed significant toxicity and no significant efficacy in patients with advanced RCC [16] . Apitolisib, another dual PI3K-mTOR inhibitor, was tested against everolimus in a phase II study with similar entry criteria to the current trial, and showed superior PFS for everolimus [17] . In both trials, rash was a common side effect, and hyperglycemia was seen more frequently with apitolisib than with everolimus. A phase I study of buparlisib, a pan-class I phosphoinositide 3-kinase inhibitor, in combination with bevacizumab showed reasonable tolerability and modest efficacy [18] . A study testing perifosine, an orally bioavailable AKT inhibitor, showed modest efficacy and acceptable toxicity in patients with advanced RCC [19] . The existence of extensive crosstalk and negative feedback mechanisms in the PI3K pathway may explain the lack of efficacy of this agent class in RCC. To identify molecular characteristics of patients on MK-2206 who exhibited PR or CR, we assessed genomic features in baseline tissue samples from our patients (supplementary Figure S3 , available at Annals of Oncology online). Our analyses demonstrated that malfunction of the DNA repair-related pathways is a poor prognostic factor in the MK-2206 group (supplementary Figure  S3 , available at Annals of Oncology online). Those pathways alterations are driven by TP53 and ATM gene modifications. There were three different deleterious mutations in our sequenced tumor samples (V143M, G266V, R273C). Those mutations are common pathogenic mutations in many other cancers and they all reside in the DNA-binding domain of TP53 [20] . The p53 protein is ubiquitinated and targeted for the degradation by the AKT-mediated phosphorylation of Mdm2 [21] . LY294002, a PI3K inhibitor, stabilizes p53 by blocking AKT activation and Mdm2 phosphorylation. In our study, we directly inhibit AKT by MK-2206. According to these results, we predict that the AKT inhibition-mediated stabilization of p53 is not useful if p53 is defective. Additionally, correlating with other studies [22, 23] , we also observe high frequency of TP53 mutations in sarcomatoid tumors, which is also associated with poor prognosis.
In summary, clinical treatment of angiogenesis inhibitorresistant patients with MK2206 is not superior to treatment with everolimus. Nonetheless, intriguing differences exist in response dynamics between patients treated with the two agents, and profound responses occurred in a subset of individuals treated with MK2206. These results indicate that potential exists for effective blockade of the PI3K pathway in patients with RCC, but considerable work is required to better understand the nuances of this pathway before we can consistently modulate it to benefit patients with RCC. In addition, or genomic data further illustrate the negative prognostic significance of mutations TP53 and DNA repair genes. This subcategory of patients clearly needs new approaches based on our emerging understanding of the significance of TP53 mutations in RCC biology.
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